Galderma announced an agreement to acquire ZO Skin Health for an enterprise value of $1.5 billion, a move designed to expand ...

Remibrutinib is approved for chronic spontaneous urticaria (CSU) and most recently, symptomatic dermographism, with the label ...

In "Recognizing EPP: Diagnostic Red Flags, Psychosocial Burden, and Confirmatory Workup," Dr. Bonkovsky turns to what should ...

Dr. Singh stresses that tolerability is key to achieving good outcomes with hedgehog inhibitors. Baseline and periodic ...

An analysis of 633 skincare brands found gaps in evidence, safety information, and claim support, raising questions about ...

Sitryx Therapeutics announced positive topline results from a Phase 1b trial of SYX-5219, a first-in-class oral pyruvate ...

In "Case 2: Escalating Therapy After Biologic Failure in HS," the panel shifts to the series' second patient case.

Adults with chronic hand eczema (CHE) treated within the Duke University Health System reported substantial work productivity ...

Cosibelimab (Unloxcyt; Sun Pharma), a PD-L1 inhibitor, is also approved for locally advanced and metastatic cutaneous ...

Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in ...

A patient with 45 percent hair loss and a wedding in six months illustrates why psychosocial burden can reclassify disease ...

Hsiao noted the options are adalimumab, a tumor necrosis factor α inhibitor; secukinumab, an IL-17A inhibitor; and ...